P86.F Paradigm Biopharmaceuticals Limited
- Market cap
- EUR 94.0M
- P/E
- -
- P/B
- 43.94x
- ROE
- -1,623.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is P86.F undervalued?
Graham numberThe Graham number of Paradigm Biopharmaceuticals Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Paradigm Biopharmaceuticals Limited fundamental analysis
No fundamental analysis for Paradigm Biopharmaceuticals Limited yet.
Paradigm Biopharmaceuticals Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Full company profileParadigm Biopharmaceuticals Limited financial statements
Paradigm Biopharmaceuticals Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 20.6K | 79.2K | 46.8K | 65.8K | 80.2K |
| Gross Profit | -78.6K | -64.5K | 27.9K | 56.8K | 68.0K |
| Operating Income | -43.4M | -48.0M | -60.0M | -65.2M | -61.3M |
| EBITDA | - | -39.2M | -51.9M | -58.5M | -53.7M |
| Net Income | -34.3M | -39.2M | -51.9M | -58.7M | -56.3M |
| EPS | -0.14 | -0.16 | -0.18 | -0.17 | -0.10 |
| Balance Sheet | |||||
| Total Assets | 84.9M | 50.7M | 67.1M | 27.4M | 30.6M |
| Total Liabilities | 6.52M | 8.38M | 13.4M | 3.58M | 27.1M |
| Shareholders' Equity | 78.3M | 42.3M | 53.7M | 23.8M | 3.47M |
| Cash & Short-term Investments | 71.0M | 39.7M | 56.3M | 17.8M | 15.4M |
| Cash Flow | |||||
| Capital Expenditure | 31.6K | 0.00 | 0.00 | 0.00 | 491K |
| Free Cash Flow | -35.0M | -32.2M | -45.2M | -65.9M | -44.2M |
| Ratios | |||||
| ROE | -43.8% | -92.8% | -96.7% | -246.4% | -1,623.0% |
| ROA | -40.4% | -77.4% | -77.4% | -214.1% | -184.4% |
| Net Profit Margin | -166,896.3% | -49,542.5% | -111,013.7% | -89,138.6% | -70,282.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Paradigm Biopharmaceuticals Limited dividends
Paradigm Biopharmaceuticals Limited has not paid dividends in the last 6 fiscal years.
Who owns Paradigm Biopharmaceuticals Limited
- Insiders 14.31%
- Institutions 4.83%
- Public & others 80.87%
- Shares outstanding 626M
- Free float 530M
Paradigm Biopharmaceuticals Limited company profile
- Company name
- Paradigm Biopharmaceuticals Limited
- Ticker
- P86.F
- ISIN
- AU000000PAR5
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 500 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9629 5566
- Website
- paradigmbiopharma.com
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Paradigm Biopharmaceuticals Limited management
8- Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTCFounder, MD & Executive Chairman · born 1959
- Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.Company Secretary & CFO · born 1982
- Dr. Ravi KrishnanChief Scientific Officer
- Mr. Simon WhiteDirector of Investor Relations
- Dr. Michael ImperialeGlobal Head of Drug Safety & MPS
- Dr. Donna L. Skerrett M.D., MSChief Medical Officer · born 1957
- Ms. Beverley HuttmannCommercial Head
- Dr. Mukesh AhujaGlobal Clinical Head of OA